Pluri (NASDAQ:PLUR) and MDxHealth (NASDAQ:MDXH) Financial Comparison

MDxHealth (NASDAQ:MDXH – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares MDxHealth and Pluri’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MDxHealth -40.84% N/A -27.78%
Pluri -1,943.87% N/A -106.56%

Insider and Institutional Ownership

16.6% of Pluri shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for MDxHealth and Pluri, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MDxHealth 1 4 1 0 2.00
Pluri 1 0 0 0 1.00

MDxHealth presently has a consensus target price of $1.33, indicating a potential upside of 794.85%. Given MDxHealth’s stronger consensus rating and higher possible upside, equities analysts plainly believe MDxHealth is more favorable than Pluri.

Valuation and Earnings

This table compares MDxHealth and Pluri”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MDxHealth $107.88 million 0.07 -$33.52 million ($0.75) -0.20
Pluri $1.02 million 13.82 -$23.82 million ($2.65) -0.37

Pluri has lower revenue, but higher earnings than MDxHealth. Pluri is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

MDxHealth has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Summary

MDxHealth beats Pluri on 9 of the 13 factors compared between the two stocks.

About MDxHealth

(Get Free Report)

MDxHealth is a molecular diagnostics company focused on tests that support the detection and management of urologic cancers, particularly prostate cancer. Its services are intended to help clinicians assess cancer risk and make more informed decisions about biopsies and treatment. The company’s products include SelectMDx, a urine-based test that helps assess the risk of clinically significant prostate cancer, and ConfirmMDx, a tissue-based test that can help guide decisions after a negative prostate biopsy.

About Pluri

(Get Free Report)

Pluri Ltd. is an Israel-based biotechnology company developing cell-based products and technologies. Its therapeutic research centers on PLX cells, derived from human placental tissue and expanded using the company’s cell-manufacturing platform. Pluri has investigated these cells for potential use in a range of medical conditions; its therapies remain in development. The company also applies its cell-expansion technology to areas beyond medicine, including food technology and agriculture, where it is exploring cell-based products and production methods.

Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.